Robert Huizinga's most recent trade in Aurinia Pharmaceuticals Inc was a trade of 106,838 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 2, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 106,838 | 106,838 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 62,448 | 62,448 | - | - | Restricted Stock Unit | |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 8,500 | 74,228 (0%) | 0% | 0 | Common Stock | |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 02 Mar 2022 | 4,849 | 69,379 (0%) | 0% | 12.0 | 58,236 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 29.75 per share. | 25 Oct 2021 | 130,000 | 65,728 (0%) | 0% | 29.8 | 3,867,500 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2021 | 95,000 | 3,864 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.20 per share. | 25 Oct 2021 | 95,000 | 195,728 (0%) | 0% | 3.2 | 304,000 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 24.05 per share. | 21 Sep 2021 | 27,136 | 106,092 (0%) | 0% | 24.1 | 652,621 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 16,000 | 0 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.63 per share. | 21 Sep 2021 | 16,000 | 122,092 (0%) | 0% | 2.6 | 42,080 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.20 per share. | 21 Sep 2021 | 11,136 | 133,228 (0%) | 0% | 3.2 | 35,635 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 11,136 | 98,864 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 23.66 per share. | 21 Sep 2021 | 5,364 | 100,728 (0%) | 0% | 23.7 | 126,912 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 21.75 per share. | 10 Sep 2021 | 22,500 | 106,092 (0%) | 0% | 21.8 | 489,375 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 10 Sep 2021 | 5,000 | 133,592 (0%) | 0% | 19.8 | 99,150 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 19.76 per share. | 10 Sep 2021 | 5,000 | 128,592 (0%) | 0% | 19.8 | 98,800 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 07 Sep 2021 | 5,000 | 138,592 (0%) | 0% | 18.3 | 91,500 | Common Stock |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | Ex Vice President of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 40,000 | 0 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Robert Huizinga | Ex Vice President of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.02 per share. | 11 May 2021 | 40,000 | 143,592 (0%) | 0% | 3.0 | 120,800 | Common Stock |